Undecsended Testicles Diagnosis Market By Surgery Type(Laparoscopy, Open Surgery), By Indication(Retractile Testicles, Ascending Testicles), and by Region and Companies Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032.

Undescended Testicles Diagnosis Market Overview:

The Undescended Testicles Diagnosis Market is projected to reach a valuation of USD 18.09 Bn by 2032 at a CAGR of 5.3%, from USD 12.60 Bn in 2021.

An undescended testicle also known as cryptorchidism is a condition in which a testicle hasn’t moved into its proper position in the scrotum before birth. It is uncommon in general, but common in baby boys born prematurely.

This condition is found in about 3-4 out of 100 newborns, and up to 21 out of 100 premature newborns. In nearly half of the babies born with this condition, testicles drop on their own to the actual position in the first 3 months after birth. But, if testicles don’t drop on their own after 3 months of age, this condition will require treatment.

A nonpalpable testicle is a testicle that cannot be felt in a physical examination. It may be in the abdomen, absent or atrophic (very small). An undescended testicle if left unattended, can cause a tumor later on in life. Surgery is the only way to find out if the testicle is present or not. Surgery can be performed in two ways either laparoscopic or open. Laparoscopic surgery is done through thin tubes inserted into a child’s body through a small incision.

A surgeon uses a special camera to see inside a child’s body. The surgeon will find one of 3 situations:

• Blind-ending testicular blood vessels – proving there’s no testicle
• Vessels leaving the abdomen – proving there’s no testicle in the abdomen
• A testicle in the abdomen. If a testicle is found, it’s brought down into the scrotum or removed, based on its condition.

The global undescended testicle market is segmented on the basis of – surgery type, indication, and region.

Listed below is this market’s detailed segmentation:

By Surgery Type

• Laparoscopy
• Open Surgery

Indication

• Retractile Testicles
• Ascending Testicles

By Region

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Russia
  • Spain
  • Rest of Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Rest of Asia-Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• MEA
  • GCC
  • South Africa
  • Israel
  • Rest of MEA

Market Dynamics

Increasing awareness levels concerning an undescended testicle and infertility are factors expected to boost the revenue growth prospects of this target market. Additionally, increasing technological innovations in the healthcare industry, coupled with significant investments by respective governments in both developed and developing nations, are other factors expected to bolster the revenue growth of the global undescended testicle diagnosis market.

Unfortunately, the high cost of treatment and low awareness levels in developing nations are factors expected to hinder this market’s economic growth to a certain extent. However, increasing R&D activities to develop devices that can detect this condition before an operation is needed is also expected to create lucrative opportunities for players in this market.

Competitive Landscape

Major players in this market are –

• Promedon HQ | Córdoba
• Sebbin
• Eli Lilly
• Implantech
• Coloplast Corp
• Baxter
• Bristol-Myers Squibb
• Pfizer
• POLYTECH Health & Aesthetics GmbH
• UROMED
• Teva Pharmaceutical
• GC Aesthetics
• and Rigicon Inc.
• among others

Key Developments:

In 2018, Thermo Fisher Scientific Inc., launched Clomid (Clomiphene citrate) under the brand name Patheon, to treat infertility in men due to cryptorchidism.